Compare · HEPA vs NVS
HEPA vs NVS
Side-by-side comparison of Hepion Pharmaceuticals Inc. (HEPA) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HEPA and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS carries a market cap of $287.12B.
- HEPA has been more active in the news (11 items in the past 4 weeks vs 6 for NVS).
- NVS has more recent analyst coverage (25 ratings vs 1 for HEPA).
- Company
- Hepion Pharmaceuticals Inc.
- Novartis AG
- Price
- -
- -
- Market cap
- -
- $287.12B
- 1M return
- -
- -3.71%
- 1Y return
- -
- +18.20%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 11
- 6
- Recent ratings
- 1
- 25
Hepion Pharmaceuticals Inc.
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest HEPA
- Amendment: SEC Form 10-Q/A filed by Hepion Pharmaceuticals Inc.
- SEC Form 10-Q filed by Hepion Pharmaceuticals Inc.
- SEC Form 4 filed by Hepion Pharmaceuticals Inc.
- SEC Form 4 filed by Hepion Pharmaceuticals Inc.
- SEC Form 4 filed by Hepion Pharmaceuticals Inc.
- SEC Form 4 filed by Hepion Pharmaceuticals Inc.
- SEC Form 4 filed by Hepion Pharmaceuticals Inc.
- SEC Form 4 filed by Hepion Pharmaceuticals Inc.
- SEC Form 4 filed by Hepion Pharmaceuticals Inc.
- SEC Form 4 filed by Hepion Pharmaceuticals Inc.
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form FWP filed by Novartis AG
- FDA Approval for LAMPRENE issued to NOVARTIS
- Novartis AG downgraded by Deutsche Bank
- SEC Form 6-K filed by Novartis AG
- Big Pharma Setbacks Create a New Wave of Rebound Plays
- Novartis AG upgraded by HSBC Securities
- Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
- RBC Capital Mkts initiated coverage on Novartis AG